These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35579947)

  • 1. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer.
    Luo Y; Li Z; Kong Y; He W; Zheng H; An M; Lin Y; Zhang D; Yang J; Zhao Y; Chen C; Chen R
    J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35579947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer.
    Pirlog R; Calin GA
    J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35838046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma.
    Kong Y; Luo Y; Zheng S; Yang J; Zhang D; Zhao Y; Zheng H; An M; Lin Y; Ai L; Diao X; Lin Q; Chen C; Chen R
    Cancer Res; 2023 Sep; 83(18):3077-3094. PubMed ID: 37363990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer.
    Chen C; Zheng H; Luo Y; Kong Y; An M; Li Y; He W; Gao B; Zhao Y; Huang H; Huang J; Lin T
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33661764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SUMOylation-triggered ALIX activation modulates extracellular vesicles circTLCD4-RWDD3 to promote lymphatic metastasis of non-small cell lung cancer.
    Diao X; Guo C; Zheng H; Zhao K; Luo Y; An M; Lin Y; Chen J; Li Y; Li Y; Gao X; Zhang J; Zhou M; Bai W; Liu L; Wang G; Zhang L; He X; Zhang R; Li Z; Chen C; Li S
    Signal Transduct Target Ther; 2023 Nov; 8(1):426. PubMed ID: 37925421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer.
    Zheng S; Tian Q; Yuan Y; Sun S; Li T; Xia R; He R; Luo Y; Lin Q; Fu Z; Zhou Y; Chen R; Hu C
    J Exp Clin Cancer Res; 2023 Nov; 42(1):324. PubMed ID: 38012734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer.
    Kong Y; Li Y; Luo Y; Zhu J; Zheng H; Gao B; Guo X; Li Z; Chen R; Chen C
    Mol Cancer; 2020 May; 19(1):82. PubMed ID: 32366257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precise and efficient silencing of mutant Kras
    Jiang W; Li H; Liu X; Zhang J; Zhang W; Li T; Liu L; Yu X
    Theranostics; 2020; 10(25):11507-11519. PubMed ID: 33052229
    [No Abstract]   [Full Text] [Related]  

  • 9. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
    Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
    PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KrasG12D-LOH promotes malignant biological behavior and energy metabolism of pancreatic ductal adenocarcinoma cells through the mTOR signaling pathway.
    Shen X; Chang LG; Hu MY; Yan D; Zhou LN; Ma Y; Ling SK; Fu YQ; Zhang SY; Kong B; Huang PL
    Neoplasma; 2018; 65(1):81-88. PubMed ID: 29322792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.
    Garcia MN; Grasso D; Lopez-Millan MB; Hamidi T; Loncle C; Tomasini R; Lomberk G; Porteu F; Urrutia R; Iovanna JL
    J Clin Invest; 2014 Nov; 124(11):4709-22. PubMed ID: 25250570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Extracellular Vesicle VEGF-C-mediated Lymphangiogenesis and Pancreatic Cancer Early Dissemination By a Selective HDAC1/2 Inhibitor.
    Wang CA; Li CF; Huang RC; Li YH; Liou JP; Tsai SJ
    Mol Cancer Ther; 2021 Sep; 20(9):1550-1560. PubMed ID: 34210825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SUMOylation-Driven mRNA Circularization Enhances Translation and Promotes Lymphatic Metastasis of Bladder Cancer.
    Zhao Y; Chen J; Zheng H; Luo Y; An M; Lin Y; Pang M; Li Y; Kong Y; He W; Lin T; Chen C
    Cancer Res; 2024 Feb; 84(3):434-448. PubMed ID: 37991737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
    Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
    Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.
    Chen SJ; Chen YT; Zeng LJ; Zhang QB; Lian GD; Li JJ; Yang KG; Huang CM; Li YQ; Chu ZH; Huang KH
    Tumour Biol; 2016 Aug; 37(8):11299-309. PubMed ID: 26951514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
    Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
    Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.
    Kumarasamy V; Wang J; Frangou C; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
    Cancer Res; 2024 Apr; 84(7):1115-1132. PubMed ID: 38294344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
    Liao J; Chung YT; Yang AL; Zhang M; Li H; Zhang W; Yan L; Yang GY
    Mol Carcinog; 2013 Sep; 52(9):739-50. PubMed ID: 22549877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.